Navigation Links
NeurogesX Announces Preliminary Results from Second Phase 3 Clinical Trial in HIV-DSP
Date:2/27/2008

ain. The Company has previously completed three Phase 3 studies in PHN, of which two met their primary endpoint. In those studies, a single, 60-minute treatment with NGX- 4010 applied directly to the site of pain reduced pain for up to 12 weeks. In addition to being studied in PHN, NGX-4010 was also studied in a successful Phase 3 clinical trial in painful HIV-DSP.

Regulatory and Commercialization Plans for NGX-4010

NeurogesX submitted an MAA, which was accepted by the EMEA under the centralized filing procedure in September 2007. The Company's MAA seeks approval in the European Union for a broad indication of peripheral neuropathic pain, which includes PHN, HIV-DSP and painful diabetic neuropathy (PDN), among others. The Company is evaluating strategies regarding its MAA that may include adding to the dossier the Company's second successful Phase 3 study in PHN and this most recent study in HIV-DSP to potentially support a broad label approval, or potentially a subset of indications. The Company expects to submit an NDA with the FDA in the second half of 2008 for PHN and will discuss with the agency the path forward for attaining approval for HIV- DSP.

NeurogesX has retained exclusive worldwide commercialization rights for NGX-4010 and intends to establish a focused specialty sales force in the United States to address its target market of pain centers and physicians. NeurogesX intends to enter into commercial partnerships for marketing and distribution outside the United States.

Conference Call and Webcast Information

A conference call to review the results of the C119 trial will begin at 5:00 p.m. EST (2:00 p.m. PST) on February 27, 2008 and will be hosted by Anthony DiTonno, President and Chief Executive Officer, Jeffrey Tobias, Chief Medical Officer, and Stephen Ghiglieri, Chief Financial Officer.

The conference call dial-in numbers are 1-877-407-0789 (USA) or 1-201-689-8562 (International). In addition, a dial-up repla
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
2. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
3. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
4. EndoGastric Solutions(TM) Announces Results of EsophyX(TM) Multi-Center GERD Study
5. Dong-A PharmTech Co., Ltd. Announces Portal Hypertension Clinical Trial With Udenafil
6. MacuSight(TM) Announces Positive Preliminary Results From Phase 1 Study of Sirolimus in Wet Age-Related Macular Degeneration
7. InteKrin Therapeutics Announces Initiation of Phase 2b Study in Type 2 Diabetes with INT131
8. amfAR Announces Funding for HIV Services and Research Aimed at Men Who Have Sex With Men in Developing Countries
9. ATS Medical Announces Initial Clinical Results of Stand-Alone Atrial Fibrillation Procedures Using ATS CryoMaze Product Line
10. ISTA Pharmaceuticals Announces Physician-Sponsored Clinical Study of Xibrom(TM) Combination Therapy with Lucentis(R)
11. Accumetrics Announces $28.8 Million Financing and Initiation of Pivotal Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... Research and Markets( ... "Deciphering Global Major Pharmaceutical Companies, New Outsourcing ... It has been publicly recognized that ... a series of challenges in the recent years. ... overcapacities in small molecule product manufacturing; increasingly challenging ...
(Date:7/7/2015)... 2015  PAREXEL International Corporation (NASDAQ: PRXL ) will ... 2015 on Wednesday, August 5 th , 2015 after the ... on PAREXEL,s website at www.PAREXEL.com and on the ... host a conference call and live webcast at 10:00 a.m. ... the results.  To access the webcast, visit PAREXEL,s website at ...
(Date:7/7/2015)...   Bionik Laboratories Corp. (OTCBB: BNKL), ... core focus in robotic exoskeleton technology for users ... today that it has completed an additional sale ... its common stock and warrants for aggregate gross ... placement transaction.  This equity financing is the sixth ...
Breaking Medicine Technology:Deciphering Global Major Pharmaceutical Companies - New Outsourcing Demands and Strategies 2Deciphering Global Major Pharmaceutical Companies - New Outsourcing Demands and Strategies 3PAREXEL International Announces Date Of Fourth Quarter And Fiscal Year 2015 Earnings Release And Conference Call 2Bionik Laboratories Completes US$13.1 Million Private Placement 2Bionik Laboratories Completes US$13.1 Million Private Placement 3
... August 10, 2011 Agendia, a commercial-stage ... St. Gallen International Breast Cancer Conference (2011) Expert Panel,s ... patients by the particular biological subtype of their tumor ... According to the panel, "it is no longer tenable ...
... August 10, 2011 The report " ... Current Trends & Forecasts (2010   -   2015) ... administration, and applications; and studies the major market drivers, restraints, ... in North America (U.S. and Canada), Europe, Asia, Japan, ...
Cached Medicine Technology:International St. Gallen Expert Panel Highlights Importance of Molecular Subtyping in Breast Cancer Treatment 2International St. Gallen Expert Panel Highlights Importance of Molecular Subtyping in Breast Cancer Treatment 3MarketsandMarkets: "Radiopharmaceuticals for Therapy and PET/SPECT Imaging" Market to reach $4,734 Million by 2015 2MarketsandMarkets: "Radiopharmaceuticals for Therapy and PET/SPECT Imaging" Market to reach $4,734 Million by 2015 3
(Date:7/7/2015)... ... ... Quadrino Law Group is pleased to announce the relocation of the firm's ... new facility is a state of the art building, located with easy access to ... and founder, said, "We are pleased to service our clients from such a premier ...
(Date:7/7/2015)... ... July 07, 2015 , ... Catalent, ... development solutions for drugs, biologics and consumer health products, today announced that ... its antibody combination therapy (ACT) technology platform. The platform has the potential ...
(Date:7/7/2015)... R.I. (PRWEB) , ... July 07, 2015 , ... Summer ... the proper precautions, however, so Amica Insurance is sharing some safety tips. , Jean ... sports and gardening: , Leisure activities/sports, , Start slowly. Going ...
(Date:7/7/2015)... ... July 07, 2015 , ... On Saturday, May 16th, 2015, the Manistee, ... Golf and Country Club. Best Drug Rehabilitation staff members were delighted to join in ... children. Kiwanis International, the parent of the Manistee Kiwanis Club, is a global organization ...
(Date:7/7/2015)... ... 07, 2015 , ... FSAstore.com today announced the launch of its ... makes it simple to use, spend and manage HSA funds with innovative tools including ... , According to a report by Devenir , approximately 13.8 million Americans have ...
Breaking Medicine News(10 mins):Health News:Catalent Biologics Adds New Technology Platform to Enable Antibody Combination Therapies 2Health News:Amica Insurance Has 7 Summer Safety Tips 2Health News:Best Drug Rehabilitation Team Participates in Kiwanis Club Golf Outing Fundraiser 2Health News:Introducing HSAstore.com: A New E-commerce Site for Health Savings Account Eligible Products and Services 2Health News:Introducing HSAstore.com: A New E-commerce Site for Health Savings Account Eligible Products and Services 3
... 5 ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA ), ... Development, will participate in a panel discussion on "Adapting Specialty ... Healthcare Conference. The panel will begin at 10:00 a.m. Eastern ... , , To ...
... Closer look at tumors boosts chances for those denied under ... News) -- Many patients with liver cancer who don,t meet ... candidates for liver transplantation, according to an Italian study. , ... single tumor of 5 centimeters or less in diameter, or ...
... reported today that 1 out of 3 American adults do not engage ... the two reasons most cited for these levels of inactivity. , ... ... conducted by the Centers for Disease Control and Prevention (CDC) 2008 Physical ...
... 5 Following a USGS study released today,showing that ... that was tested, the Water Quality Association is encouraging ... According to a report by ... chemicals were not removed by public treatment processes. ...
... PORTLAND, Ore., Dec. 5 Dozens of striking Oak ... rally yesterday on the strike line at Portland,s Oak Harbor Freight ... at Oak Harbor Freight for the past 11 weeks and recently ... , "We believe our retirees have upheld ...
... Fla., Dec. 5 In recognition of the best,Florida ... Blue Foundation for a Healthy Florida, the philanthropic affiliate,of ... announced its 2008,Sapphire Award honorees at a ceremony in ... http://www.newscom.com/cgi-bin/prnh/20050112/NEW019LOGO ) , ...
Cached Medicine News:Health News:New Criteria Could Expand Number of Liver Transplant Candidates 2Health News:Exceeding the Government's Minimum Health Guidelines with a Treadmill Desk 2Health News:Exceeding the Government's Minimum Health Guidelines with a Treadmill Desk 3Health News:Chemicals Remain in Most Treated Water, Says Report 2Health News:Striking Oak Harbor Employees Honor Retirees 2Health News:Florida's Top Health Care Nonprofits Honored With 2008 Sapphire Awards 2
50L...
... Hamilton is precision, ergonomics, and ... hand fatigue with soft non-slip, contoured ... with smooth, light plunger spring action ... and sterilization without the need for ...
... 2000 Pipette is a synonym for pipetting ... robust design, and superior operating comfort. Its ... the measuring stroke and blow-out as well ... system ensures utmost accuracy and precision. Ejection ...
250L...
Medicine Products: